T-Cell Non-Hodgkin Lymphoma — Trials

T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 225
Recruiting: 127
Ph III recruiting: 9
Growth YoY: +23.4%
Industry share: 21%
Top sponsor: Institute of Hematology & Blood Diseases Hospital, China
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 651–700 of 1,008 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01561833	A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients	completed	Phase 1	12	Yale UniversityOTHER	1	Aug 13, 2020	clinicaltrials
NCT04233697	Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma	withdrawn	Phase 1	0	Columbia UniversityOTHER	0	Aug 13, 2020	clinicaltrials